Krilogy Financial LLC Sells 24,280 Shares of Zoetis Inc. $ZTS

Krilogy Financial LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 88.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,256 shares of the company’s stock after selling 24,280 shares during the quarter. Krilogy Financial LLC’s holdings in Zoetis were worth $403,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Diamond Hill Capital Management Inc. bought a new position in shares of Zoetis during the third quarter valued at $394,010,000. Nordea Investment Management AB increased its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Zoetis by 83.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after acquiring an additional 1,227,085 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after acquiring an additional 1,191,840 shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Zoetis by 342.1% during the third quarter. First Trust Advisors LP now owns 1,485,459 shares of the company’s stock valued at $217,352,000 after acquiring an additional 1,149,467 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 1.3%

Zoetis stock opened at $116.01 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23. The stock has a market capitalization of $48.80 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. The business’s fifty day moving average is $121.02 and its 200 day moving average is $125.73.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the firm posted $1.40 earnings per share. Zoetis’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 7.02 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ZTS shares. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and a consensus target price of $152.25.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.